CAV1 and pancreatic neoplasm: Dasatinib failed to show any significant activity in a phase 2 trial in non-selected patients with advanced pancreatic cancer.[28] Preclinical studies using patient-derived xenografts (PDX) identified high expression of caveolin-1 in PDX sensitive to bosutinib.